Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum TC BioPharm (Holdings) plc TCBP

TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{currentVideo.storiesTitle}}:
{{story.companySymbol}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 

TCBP ....on watch after retracement

73 pesos  rate and reply

$TCBP News Clips

Orphan drug status is a designation granted by the Federal Drug Administration for therapies targeting rare diseases. The status allows for a seven-year exclusive marketing window post approval of the...read more

$TCBP News clips

"This is another milestone achieved by TC BioPharm, further strengthening our leadership position in Gamma Delta therapies for oncology," stated CEO Bryan Kobel. "The granting of...read more

$TCBP News clips

   rate and reply

$TCBP News clips

EDINBURGH, Scotland, March 17, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage...read more

$TCBP News clips

Dr. Michael Leek, Founder and Executive Chairman commented, "Apart from matched bone-marrow stem cell transplants, patients with unresponsive AML are presented with few viable...read more

$TCBP News clips

The two patients exhibiting complete response and stable disease were re-dosed with allogeneic product, and the patient with and morphologic leukemia-free state received two further infusions of...read more

$TCBP News clips

Clinical data provided evidence of good safety and tolerability profile of OmnImmune® as no product related safety concerns were raised during Safety Review Committee meetings. Moreover, no graft...read more

$TCBP News clips

Allogeneic gamma-delta T cell persistence was evaluated in two patients treated. In one patient allogenic product remained detectable after 100 days following three infusions. Another patient...read more

$TCBP News clips

 Our Phase 2b/3 trial will take this therapeutic another step further, incorporating our frozen/thawed product generated from our proprietary universal cell banks of gamma deltas, for a true...read more

$TCBP News clips

"These results are very encouraging in such late-stage unresponsive patients, most of whom had very advanced cancer, were fourth or fifth line with no further therapeutic options," said ...read more

$TCBP News clips

"We are extremely pleased to receive such positive data from our phase 1b/2a study demonstrating OmnImmune® as safe and tolerable among patients with advanced acute Myeloid...read more

$TCBP News clips

Of the 7 patients treated, three received OmnImmune®, at a low-dose and four received OmnImmune®, at a higher dose of cells. In the low dose cohort one patient achieved MLFS...read more

$TCBP News clips

7 patients received treatment and 2 patients (enrolled in the low dose cohort) did not reach day 28 assessment and were not evaluable for efficacy per protocol with the third patient being available...read more

$TCBP News clips

A clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, announces positive interim data its Phase 1a/2b human...read more